ArticleIranian journal of biotechnology2025
Co-Infection of
Article in Iranian journal of biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate why the recombinant coat protein (CP) of Materials and Methods: Three open reading frames (ORFs) of the CMV genome-encoding the coat protein (CP), movement protein (MP), and 2b protein-were amplified by RT-PCR, cloned into a ZYMV-based vector, and expressed in squash plants ( Results: The expression of CMV CP by the ZYMV vector altered symptom development but was undetectable by immunoassays and immunoblotting in all treatments except in the presence of wild-type CMV. Immuno-gold electron microscopy revealed that the recombinant CPs were incorporated into virus particles, suggesting that their stabilization occurred through binding to RNA. Conclusion: Our results indicate that CMV-MP and -2b do not contribute to CP stabilization. Instead, we propose that the recombinant CP is stabilized by participating in virus particle assembly, as it is an RNA-binding protein. The IGEM results, showing gold particles attached to CMV particles, confirm that the recombinant CMV-CPs bind to RNA and integrate into CMV particles, leading to their stabilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.